OCALIVA (obeticholic acid) Intercept pharms inc Patent: 7,138,390 Expiration: Nov 16, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…
The post Drug Patent Expirations f…
Drug Patent Expirations for the Week of November 13, 2022 Read Post »
Annual Drug Patent Expirations for AMITIZA Amitiza is a drug marketed by Sucampo Pharma Llc and is included in one NDA. It is available from four suppliers. There are nine…
The post New patent expiration for Sucampo Pharma drug AMITIZA appeared first o…
New patent expiration for Sucampo Pharma drug AMITIZA Read Post »
OCALIVA (obeticholic acid) Intercept pharms inc Patent: 7,138,390 Expiration: Nov 16, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…
The post Drug Patent Expirations f…
Drug Patent Expirations for the Week of November 13, 2022 Read Post »
OCALIVA (obeticholic acid) Intercept pharms inc Patent: 7,138,390 Expiration: Nov 16, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…
The post Drug Patent Expirations f…
Drug Patent Expirations for the Week of November 13, 2022 Read Post »
Annual Drug Patent Expirations for CHANTIX Chantix is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from four suppliers. There are two…
The post New patent expiration for Pf Prism drug CHANTIX appeared first on DrugPatentWa…
Annual Drug Patent Expirations for HORIZANT Horizant is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are six patents protecting…
The post New patent expiration for Azurity drug HORIZANT appeared first …
OSPHENA (ospemifene) Duchesnay Patent: 9,566,252 Expiration: Nov 2, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit…
The post Drug Pat…
Drug Patent Expirations for the Week of October 30, 2022 Read Post »
OSPHENA (ospemifene) Duchesnay Patent: 9,566,252 Expiration: Nov 2, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit…
The post Drug Pat…
Drug Patent Expirations for the Week of October 30, 2022 Read Post »
Annual Drug Patent Expirations for OSPHENA Osphena is a drug marketed by Duchesnay and is included in one NDA. It is available from one supplier. There are eight patents protecting…
The post New patent expiration for Duchesnay drug OSPHENA appeared fir…
New patent expiration for Duchesnay drug OSPHENA Read Post »
Annual Drug Patent Expirations for RYDAPT Rydapt is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting…
The post New patent expiration for Novartis drug RYDAPT appeared first on…